How industry uses the ICMJE guidelines to manipulate authorship-and how they should be revised

PLoS Medicine

Volumn 8, Issue 8, 2011, Pages

  Matheson, Alastair ^a,b  

^a Independent Consultant   (United Kingdom)

^b Independent Consultant   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; DOCUMENTATION; GHOSTWRITING; INFORMATION PROCESSING; MEDICAL LITERATURE; ORGANIZATION; PRACTICE GUIDELINE; PUBLICATION; PUBLISHING; RESEARCH ETHICS; SCIENTIFIC MISCONDUCT; WRITING; DRUG INDUSTRY; ETHICS; HUMAN; ORGANIZATION AND MANAGEMENT; PERSONNEL; STANDARD;

AUTHORSHIP; DRUG INDUSTRY; EDITORIAL POLICIES; GUIDELINES AS TOPIC; HUMANS; PUBLISHING; RESEARCH PERSONNEL;

EID: 80052322975     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001072     Document Type: Article

References (27)

1. International Committee of Medical Journal Editors (1985) Guidelines on authorship. BMJ 291: 722.
2. International Committee of Medical Journal Editors (2011) Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publications. Available: http://www.icmje.org/. Accessed 6 July 2011.
3. Davidoff F, DeAngelis CD, Drazen JM, Nicholls MG, Hoey J, et al. (2001) Sponsorship, authorship and accountability. CMAJ 165: 786-788.
4. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. (2005) Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet 365: 1827-1829.
5. Drazen JM, de Leeuw PW, Laine C, Mulrow C, DeAngelis CD, et al. (2010) Toward more uniform conflict disclosures--the updated ICMJE conflict of interest reporting form. N Engl J Med 363: 188-189.
6. Matheson AD, (2008) Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties 3: 355-382.
7. Fugh-Berman AJ, (2010) The haunting of medical journals: how ghostwriting sold "HRT". PLoS Med 7 (9): e1000335 doi:10.1371/journal.pmed.1000335.
8. The PLoS Medicine Editors (2009) Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med 6 (9): e1000156 doi:10.1371/journal.pmed.1000156.
9. Sismondo S, Doucet M, (2010) Publication ethics and the ghost management of medical publication. Bioethics 24: 273-283.
10. Egilman D, Druar N, (2011) Corporate versus public interests: community responsibility to defend scientific integrity. International Journal of Occupational and Environmental Health 17: 181-185.
11. Moynihan R (2008) Key opinion leaders: independent experts or drug representatives in disguise? BMJ 336: 1402-1403.
12. Rennie D, Yank V, Emanuel L, (1997) When authorship fails. A proposal to make contributors accountable. JAMA 278 (7): 579-585.
13. Smith R, (1997) Authorship is dying: long live contributorship. BMJ 315: 696.
14. World Association of Medical Editors (2005) Ghost writing initiated by commercial companies. Available: http://www.wame.org/resources/policies#ghost. Accessed 6 July 2011.
15. Council of Science (2009) White paper on promoting integrity in scientific journal publications. Available: http://www.councilscienceeditors.org/i4a/pages/index.cfm?pageid=3355. Accessed 6 July 2011.
16. International Society for Medical Publication Professionals Issues and Actions Committee (2010) Professional medical writing. Available: http://www.ismpp.org/initiatives/Files/ISMPP_Ghost_Writing_vs_Professional_Medical_Writing.pdf. Accessed 6 July 2011.
17. European Medical Writers Association Ghostwriting positioning statement. Available: http://www.emwa.org/Home/Ghostwriting-Positioning-Statement.html. Accessed 6 July 2011.
18. American Medical Writers Association (2009) AMWA ethics FAQs. Available: http://www.amwa.org/default.asp?Mode=DirectoryDisplay&DirectoryUseAbsoluteOnSearch=True&id=466. Accessed 6 July 2011.
19. Ilakovac V, Fister K, Marusic M, Marusic A, (2007) Reliability of disclosure forms of authors' contributions. CMAJ 176: 41-46.
20. Pharmaceu Reasearch and Manufacturers of America (2009) Principles on conduct of clinical trials. Communication of clinical trial results. Washington (D.C.)Pharmaceutical Research and Manufacturers of America Available: http://www.phrma.org/sites/default/files/105/042009_clinical_trial_principles_final.pdf. Accessed 6 July 2011.
21. Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, et al. (2009) Research methods & Reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 339: b4330 doi:10.1136/bmj.b4330.
22. Jacobs A, Wager E, (2005) European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 21 (2): 317-322.
23. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, et al. (2009) What should be done to tackle ghostwriting in the medical literature? PLoS Med 6 (2): e1000023 doi:10.1371/journal.pmed.1000023.
24. British Medical Journal (2011) Article submission. Provenance of articles. Available: http://resources.bmj.com/bmj/authors/authors/article-submission/submitting-an-article-to-the-bmj#provenance. Accessed 6 July 2011.
25. World Association of Medical Editors (2007) Authorship. Available: http://www.wame.org/resources/policies#authorship. Accessed 6 July 2011.
26. Neurology (2010) Information for authors. Available: http://www.neurology.org/misc/auth2.xhtml. Accessed 6 July 2011.
27. Proceedings of the National Academy of Sciences (2011) Information for authors. Journal policies. Authorship. Available: http://www.pnas.org/site/misc/iforc.shtml#ii. Accessed 6 July 2011.